CT scan findings according to established criteria. 19, 20 Subjects were classified as having a severe TBI if their GCS score was < 9, regardless of CT scan findings. Subjects were classified as having had a moderate TBI if they had a GCS of 9-12 regardless of CT findings, or if they had a GCS of 13-15 and a positive CT scan. 21, 22 Subjects were classified as having a moderate/ severe TBI if they had a positive CT scan but there was no GCS available to make a finer characterization. Subjects were classified as having a mild TBI if their GCS score was 13-15 and the CT scan was negative.
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METHODS
Sleep Studies
An Epworth Sleepiness Score (ESS) questionnaire 23 was completed by each subject on the night of polysomnography. Nocturnal polysomnograms (NPSG) were performed ≥ 3 months post injury in sleep laboratories in each center. Using standard techniques, 24 ,25 a computer data acquisition and analysis system recorded the following signals: electroencephalogram (C3A2, C4A1, O1A2, and O2A1), bilateral electroculogram, submental and bilateral anterior tibialis electromyogram, thoracic and abdominal excursion by piezocrystals, oral and nasal airflow by thermistor and breath sounds, body position, oxygen saturation by pulse oximeter, and electrocardiogram. Throughout the study, subjects were monitored with an infrared video camera and a one-way intercom, which connects the bedroom with the monitoring room. All studies were attended by polysomnographic technologists who also scored the studies using 30-sec epochs by Rechtschaffen and Kales criteria, 26 and each was interpreted by a physician certified by the American Board of Sleep Medicine.
During the day subsequent to the sleep study, a multiple sleep latency test (MSLT) was used to assess objective physiologic sleepiness. The test was performed using standard techniques; sleep onset was defined as the first epoch of sleep, (> 50% of the 30-sec epoch of any sleep stage). 27 Each subject took 5 naps of 20-min duration at 2 hour intervals. The following signals were recorded during the naps: EEG (C3A2, C4A1, O1A2 and O2A1), bilateral electroculograms, submental electromyogram, and electrocardiogram. The average sleep latency over these 5 naps was the MSLT score. Those with an MSLT score < 10 min were termed sleepy and those with an MSLT score ≥ 10 min were non-sleepy. A urine sample was collected after the NPSG and during the MSLT with analysis for possible opiates, benzodiazepines, cannabinoids, amphetamines, and adrenergic drugs.
Respiratory events were scored as previously described.
28
Obstructive apnea was defined by cessation of breathing > 10 sec with ≥ 4% fall in oxygen saturation and/or EEG arousal accompanied by continuous respiratory effort. Central apnea was defined by a cessation of breathing > 10 sec with ≥ 4% fall in oxygen saturation and/or EEG arousal without respiratory effort. Hypopnea was defined as > 50% reduction in airflow > 10 sec accompanied by ≥ 4% fall in oxygen saturation and/or EEG arousal. The diagnosis of obstructive sleep apnea (OSA) was made with ≥ 5 apneas/hour of sleep and/or ≥ 10 apneas + hypopneas/hour of sleep. Narcolepsy was defined as an MSLT score (average sleep latency) < 5 min with ≥ 2 sleep onset REM periods (SOREMPs) after an unremarkable NPSG with adequate total sleep and REM sleep and negative urine drug screen. Posttraumatic hypersomnia (PTH) was defined as an MSLT score ≤ 10 min with < 2 SOREMPs after an unremarkable NPSG and no history of hypersomnolence prior to TBI. Periodic limb movements in sleep (PLMS) were defined as > 5 periodic limb movements (PLMs)/hour of sleep; PLMs were scored according to the standard criteria prevailing at the time the study was designed and initiated.
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Neuropsychological Evaluation
Each subject underwent a brief neuropsychological evaluation and completed several self-report measures. All subjects were evaluated on 2 occasions. To control for diurnal variations, all evaluations took place beginning at 10:30, between the second and third MSLT naps. The measures used are described below.
Psychomotor Vigilance Test (PVT): Sustained attention was evaluated with the Psychomotor Vigilance Test (PVT). The PVT was chosen because it is sensitive to the effects of sleepiness on cognitive functioning as well as cognitive problems associated with OSA and its treatment. [31] [32] [33] The PVT is administered via a small hand-held computerized device with a 3-digit millisecond LED counter and display window (PVT-192: Ambulatory Monitoring Inc, Ardsley, NY). Subjects are presented with a 10-min trial in which they press a response button as soon as a number counting up from 0 is seen. Once the response button is pressed, the counter stops and feedback is given on their reaction time. The amount of time between stimulus presentations varies between minimum and maximum interstimulus intervals of 2000 and 10,000 ms. Performances are recorded in the PVT device and downloaded into a database after the testing bout. For the purposes of this study, the average of the fastest 10% of reaction times, the average of the slowest 10% reaction times, and the number of lapses (reaction times > 500 ms) from the PVT were selected for this analysis because these variables have been shown in prior research to be sensitive to sustained attention under conditions of sleep deprivation and in sleep disorders. [31] [32] [33] Normally, the PVT is given in several testing bouts across time. Owing to the time constraints involved in this study, each subject was exposed to the PVT once.
Profile of Mood States (POMS): The Profile of Mood States (POMS)
34 is a self-report measure in which subjects rate themselves on each of 65 adjectives using a 1-5 scale. These 65 responses yield 6 mood state scales which are: Anger-Hostility; Vigor-Activity, Depression-Dejection, Fatigue-Inertia, Tension-Anxiety, and Confusion-Bewilderment. This measure enjoys wide use in sleep research and has been shown to be sensitive to sleep disorder-related mood problems.
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Functional Outcome of Sleep Questionnaire (FOSQ): The Functional Outcome of Sleep Questionnaire (FOSQ) is a selfreport measure designed to assess the impact of sleep disorders on daily functioning. 37 It has been used in sleep research and appears sensitive to treatment related change. [38] [39] [40] There are 30 items, which are divided into 5 scales: Activity, Vigilance, General Productivity, Social Outcome, and Intimacy and Sexual Relationships. These scales are summed to make a total score.
Treatment of Sleep Disorders after TBI
Higher scores on the FOSQ indicate self-perceived better daily functioning. The total score was used for this analysis.
Patients with diagnosed sleep disorders were offered one of the following treatment plans: (1) OSA patients were treated with nasal continuous positive airway pressure (CPAP) and returned subsequent to diagnosis for repeat NPSG with appropriate titration of CPAP to eliminate apneas, hypopneas, and snoring; (2) Subjects with PLMS were treated with pramipexole 0.375 mg by mouth each night; (3) Those diagnosed with narcolepsy or PTH were treated with modafinil 200 mg by mouth each morning. The patients were not seen in closer follow-up unless there was an adverse event. Thus medications were not titrated up or down.
Three-Month follow-up
The patients were re-examined after ≥ 3 months of treatment. Those subjects without a sleep disorder were also seen at 3 months. The sleep study, MSLT, and neuropsychologic evaluation were repeated in those patients with a sleep disorder. Those without a sleep disorder participated in the neuropsychologic testing only.
STATiSTicAL ANALYSiS
Comparability of demographic and baseline characteristics were summarized by subgroups using means and standard deviations (quantitative data), or frequency of counts (qualitative /categorical data). Parametric t tests for independent samples were used to evaluate group differences when distributions were normal. Categorical data was analyzed using chi square tests. Where small cell sizes precluded the use of chi square, Fisher exact test was employed.
RESULTS
Overview of the Sample
There were 87 subjects initially studied, of whom a total of 57 patients completed the protocol (Figure 1 ). Of those, 35 subjects (61%) were free of a sleep disorder, 13 (23%) had OSA, 3 (5%) had narcolepsy without cataplexy, 2 (3%) had PTH, and 4 (7%) had PLMS. There were 12 (25%) female and 36 (75%) male participants. Forty-four subjects (77%) were Caucasian, 8 (14%) were African American, and 5 (9%) were Hispanic. Of those who had complete data upon which severity could be determined, 17 subjects (30%) had severe injuries, 3 (5%) had moderate or severe injury, 10 (18%) had moderate injuries, and 5 (9%) had mild injuries. Forty-four (77%) subjects incurred TBI as a result of a motor vehicle accident, 4 (7%) were assaulted, 5 (9%) had a fall, and 4 (7%) were injured by a falling object. The average age, education, and number of months post injury for the entire sample were 38.56 (± 14.75) years, 12.65 (± 1.88) years, and 67.84 (± 126.34) months.
Did Patients improve?
We next evaluated the degree to which TBI patients with sleep disorders benefited from treatment. Baseline sleep and demographic data are depicted in Tables 1 and 2 . In order to determine if OSA patients were effectively treated, the apnea hypopnea index (AHI), amount of REM sleep, MSLT, and ESS were compared pre and post treatment using a paired samples t test. These comparisons disclosed that the AHI improved dramatically from pretreatment to post treatment (p = 0.001). The amount of REM sleep increased from pre to post treatment (p = 0.04), but there was no change in total sleep time (p = 0.38). The results of group comparisons of the outcome measures disclosed: (1) a significant difference in the amount of change in POMS Tension and Anger scales, indicating that the sleep disordered patients had greater reductions in tension and anger than the non sleep disordered patients (p = 0.04); (2) that the sleep disordered patients showed a marginally significant greater reduction in self-reported sleepiness on the ESS (p = 0.05); (3) that the sleep disordered patients did not differ from the non-sleep disordered patients in the amount of change from pre to post treatment on the FOSQ or the PVT measures (all p > 0.05). However, given the number of statistical comparisons performed, these differences are likely the result of chance.
Sleepy and Non-Sleepy Patients
There were 12 sleepy and 10 non-sleepy patients who completed the study. There were 16 males and 6 females in the sam- There was no significant change in MSLT score (p = 0.66) or ESS (p = 0.43). In order to determine if there had been significant treatment related improvement in those with narcolepsy and PTH, the pre and post treatment MSLT and ESS scores were evaluated using a paired samples t test for the pooled group. These findings disclosed no statistically significant differences from pretreatment to posttreatment on the MSLT or the ESS. However the mean MSLT scores increased from 5.65 ± 1.7 to 9.3 ± 6.9 min in this small group from before treatment to after treatment with modafinil 200 mg daily for narcolepsy or PTH. There were improvements in MSLT scores in one of 3 narcolepsy subjects (from 4.3 to 19 min) and one of 2 PTH subjects (from 6 to 13 min). To determine if there had been a significant treatment-related improvement in those with PLMS, pre and post treatment periodic limb movement index (PLMI) as well as the ESS and MSLT scores were compared using a paired samples t test. These findings revealed a significant decrease in the PLMI from pre (17.7 ± 7.2) to post treatment (1.25 ± 2.5) with 0.375 mg of pramipexole (p = 0.03). There was no significant change in MSLT score from pre (13.1 ± 3.6) to post treatment (13.2 ± 7.7) in this patient group, but these were normal MSLT scores at the outset.
Outcome Of Sleep Disordered And Non-Sleep Disordered Patients: Neuropsychology And Quality Of Life Measures
In order to examine the relationship between sleepiness, cognitive functioning, mood state, and quality of life, the FOSQ total score, the 6 scales from the POMS, and the average of the fastest 10% of reaction times, the average of the slowest 10% reaction times, and the number of lapses (reaction times > 500 ms) from the PVT were selected for this analysis. The amount of change from pretreatment to post treatment served as the dependent measure in these analyses. The distributions are depicted in Table 3 . This analysis was based on 22 sleep disordered and 33 non-sleep disordered patients. The average RJ Castriotta, S Atanasov, MC Wilde et al jects and one of 2 PTH subjects demonstrated resolution of hypersomnia by MSLT with modafinil 200 mg daily. There were no significant changes in measures of mood, quality of life and cognitive performance in TBI patients after treatment of their sleep disorders. There are a number of methodological factors that must be considered in evaluating these results.
is the MSLT the Right Outcome Measure?
We are not the first investigators to find that the MSLT does not change with treatment. In a trial of modafinil for the treatment of residual excessive daytime sleepiness in obstructive sleep apnea, modafinil had no effect on sleepiness as measured by the multiple sleep latency test; however, significant improvements in alertness were found with the maintenance of wakefulness test. 41 In another study, 42 142 patients with sleep apneahypopnea syndrome (AHI = 10-30) were randomly assigned to (± 1.42) and 13.10 (± 2.77); and 66.80 (± 148.61) and 83.70 (± 106.62). The distributions of gender, severity, race, and cause of injury were all similar between the groups (p > 0.05). There were no differences between the groups in terms of age, education, number of months post injury, and GCS. To examine the relationship between sleepiness, cognitive functioning, mood state, and quality of life, the FOSQ total score, the 6 scales from the POMS and the average of the fastest 10% of reaction times, the average of the slowest 10% reaction times, and the number of lapses (reaction times ≥ 500 ms) from the PVT were selected for this analysis. The amount of change from pretreatment to post treatment served as the dependent measure in these analyses. The distributions for demographic and outcome data are depicted in Table 6 . Note that there were missing PVT data and thus, this analysis was based on 8 sleepy and 11 non-sleepy patients. The results of these group comparisons disclosed no significant differences between the groups on any of the measures (all p > 0.05).
DiScUSSiON
In this paper, we report the results of a prospective evaluation of unselected traumatic brain injury patients with PSG, MSLT, ESS, and neuropsychological as well as functional outcome measures before and after treatment of OSA, narcolepsy, PTH, and PLMS. An analysis of pre and post treatment results disclosed a polysomnographic reversal of OSA with CPAP and in PLMS with pramipexole. In subjects with OSA there was no demonstrable improvement in excessive daytime sleepiness as defined by the MSLT or ESS after treatment with CPAP, despite polysomnographic resolution of OSA. One of 3 narcolepsy sub- but we did not measure the MWT to obtain this data. In support of this view, the meta-analysis reported above found improvement by MWT in spite of observing no change in MSLT with CPAP treatment. 45 On the basis of our study and what has been discussed above, it is possible that the MWT may be a better outcome measure than MSLT in future clinical trials. While there was an improvement of borderline significance (p = 0.05) in ESS, there is good reason to doubt the validity of self-report in this patient population. 
Treatment of Sleep Disorders after TBI
Other Methodological issues
The sample sizes were small, and, in addition, complete data on severity of injury was not available on all subjects. For this reason we were unable to address the possibility of a relationship between injury severity and outcome of treatment for sleep disorders. We did not have sufficient numbers to evaluate outcomes in narcolepsy and PTH. Significant effects might have been detected with larger sample sizes. In this study we planned to recruit 90 TBI subjects, expecting that approximately 40% would have sleep disorders and excessive daytime sleepiness. In actuality, 47% had sleep disorders, but only 26% had excessive daytime sleepiness as measured by MSLT. Of those who returned for the second study, 39% had a sleep disorder and 21% had excessive daytime sleepiness. There was an attrition rate of 35% between the initial evaluation and the post treatment phase. This is not unusual for research with TBI patients. Future investigations of TBI patients and sleep disorders need to recruit very large numbers of TBI patients in order to adequately sample the heterogeneity of sleep disorders in this population. This would be best and most economically accomplished with large-scale multicenter investigations by collaborative investigators.
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While CPAP treatment of OSA patients was properly titrated in the laboratory, dosages of modafinil and pramipexole were fixed a priori by the study protocol with no accommodation made for individual responses and related dose titration. For this reason, patients with PTH or narcolepsy may have been undertreated and remained sleepy on the 200 mg dose of modafinil, yet might have improved with a higher dose. However, titration of modafinil would have required accurate self-report from receive conservative treatment (sleep hygiene and weight loss) or conservative treatment plus CPAP. There was no significant improvement in MSLT scores in the CPAP group at 3 and 6 months. A trial conducted to assess the efficacy of modafinil (200-400 mg/day) for the treatment of EDS in Parkinson disease failed to show a significant improvement in MSLT scores compared with placebo.
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A review of 75 studies concluded that MSLT and MWT have limited clinical utility for confirming response to treatment in groups of patients with different sleep disorders.
44 A meta-analysis 45 of randomized controlled trials where CPAP was compared with either a placebo or with conservative management in the treatment of OSA showed that CPAP: (1) significantly reduced subjective daytime sleepiness (ESS), (2) improved objective daytime wakefulness (MWT), but (3) did not affect objective daytime sleepiness (MSLT).
Why is the MSLT Unresponsive to Treatment?
One explanation may be that sleep and wakefulness are 2 separate active processes. The active process of sleep and propensity to fall asleep are measured by MSLT. The active process of wakefulness and the ability to stay awake are measured by MWT. It is possible that CPAP and modafinil treatment did not affect the propensity to fall asleep as measured by MSLT. Both treatments may have enhanced the ability to stay awake, RJ Castriotta, S Atanasov, MC Wilde et al 
